18 October 2021 - The TGA has provisionally approved the use of the Roche combination therapy, casirivimab + imdevimab (Ronapreve) for the treatment and prevention of COVID-19 in specific target populations.
Ronapreve now has provisional approval for treating adults and adolescents aged 12 years and older and weighing at least 40 kg who do not require supplemental oxygen for COVID-19 and who are at increased risk of progressing to severe COVID-19.